Nacamed develops innovative technology that can improve the performance of various types of drug substances.

We enhance drug substances that are currently under development, as well as challenging established drug substances that have already been through safety and efficacy studies in humans.

Research & Development Pipeline

Nacamed's pipeline includes:

  • Oral delivery of poorly soluble drugs (Preclinical stage)

  • Oral delivery of hydrogen gas (Preclinical stage)

  • Exploratory research on immune-modulating drugs (Animal studies)

  • Dual delivery of hydrogen gas and pharmaceutical compounds (Preclinical stage)

Delivery of poorly soluble drugs

Poor solubility is considered one of the major challenges in drug development. An estimated 40% of drugs on the market and 90% of drugs under development have insufficient water solubility. This can lead to poor oral bioavailability, high dosing, high cost, gastrointestinal side effects, drug interactions and potential environmental problems.

The Nacamed particles can capture and stabilize a crystal form of these drugs with faster dissolution upon oral delivery. This improves the oral uptake of the drug and results in improved dose-response, reduced side effects and lowered costs.

Hydrogen Delivery with silicon nanoparticles

As an antioxidant hydrogen can reduce the amount of oxidative stress in addition to possessing several other homeostasis-promoting mechanisms. Hydrogen therapy has shown positive indications in clinical trials in the treatment of cardiovascular diseases, cancer, respiratory diseases, central nervous system disorders, infections and many more.

The available hydrogen administration methods are limited due to the poor water solubility and the explosive hazard when mixed with oxygen.

Administration of an oral formulation containing the Nacamed particles offers a feasible way to safely and efficiently deliver large doses of hydrogen for disease treatment.

Ongoing projects in explorative phases

Immunology

The understanding of Immune related diseases has during the last two decades resulted in several new approved drug products with disease-modifying effects on many common diseases. 

An area of specific interest for Nacamed is the immunomodulating drugs. Preliminary data show that silicon nanoparticles might have a potential within immunological related diseases and immunological effects of drugs.

 

Dual delivery

An exploratory research project in Nacamed is based on dual delivery of both hydrogen gas and classical drug substances from the same nanoparticles. Further studies related to possible synergistic effects are in progress.